Sarepta Therapeutics (NASDAQ:SRPT) Given “Sell” Rating at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports.

Other analysts have also issued research reports about the stock. Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. Wedbush upped their target price on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday. Wells Fargo & Company decreased their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Guggenheim dropped their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada raised their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $33.84.

Sarepta Therapeutics Stock Up 7.9%

Shares of NASDAQ SRPT opened at $22.80 on Tuesday. The stock has a market capitalization of $2.39 billion, a P/E ratio of -7.57, a PEG ratio of 0.52 and a beta of 0.48. The stock’s fifty day moving average is $21.22 and its 200 day moving average is $19.83. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $120.05. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The company’s revenue for the quarter was down 14.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SRPT. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at approximately $25,000. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the last quarter. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the 3rd quarter worth about $33,000. Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares during the period. Finally, Parallel Advisors LLC raised its position in shares of Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 1,256 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company announcement — Sarepta reported positive topline 3‑year EMBARK results showing ELEVIDYS significantly slows disease progression on key functional measures versus an external control, which drove the immediate market rally. Sarepta Announces Positive Topline Three-Year EMBARK Results
• Positive Sentiment: Analyst/upgrades and media momentum — Coverage from major outlets and a Zacks upgrade to a Buy (Zacks Rank #2) amplified optimism and likely supported buying interest after the readout. Sarepta Therapeutics (SRPT) Upgraded to Buy
• Neutral Sentiment: Valuation check — Analysts and commentators are reassessing SRPT’s valuation after the short‑term share momentum; watch multiples and forward estimates for follow‑through. Assessing Sarepta Therapeutics (SRPT) Valuation
• Neutral Sentiment: Full data/transcript available — A Seeking Alpha transcript and other detailed writeups are available for investors who want drill‑down on endpoints, statistical significance and subgroup effects. These details will matter for longer‑term conviction. EMBARK Phase 3 Transcript
• Negative Sentiment: Citi Sell / safety & label risk — Citi’s Yigal Nochomovitz issued a Sell / high‑risk rating, arguing that safety uncertainty and potential label restrictions could overshadow the positive efficacy data. That bearish stance increases downside risk despite the readout. Sarepta Therapeutics: Safety Uncertainty and Label Risk
• Negative Sentiment: Regulatory / safety backdrop — ELEVIDYS previously faced FDA restrictions to ambulatory patients after acute liver‑injury deaths in non‑ambulatory patients; investors should weigh the readout against this prior safety signal and the potential for labeling or post‑market requirements. Investors Brace for Pivotal Monday Data Release

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.